Sinovac, a Beijing-based company producing a vaccine for COVID-19 since January 2020 today announced their "CoronaVac" vaccine concluded preliminary phase I/II trials showing "favorable immunogenicity and safety profiles."
The randomized, double-blind, and placebo-controlled trials comprised 143 volunteers in phase I and 600 volunteers in phase II. In each group, participants were verified healthy and aged 18 to 59.
Earlier this week, Sinovac also announced they reached an agreement to start their final phase III of testing in Brazil, staying in pace with leading vaccine manufacturers like Moderna and AstraZeneca.
“Our phase I/II study shows CoronaVac is safe and can induce immune response." said Mr. Weidong Yin, Chairman, President and CEO of Sinovac, "Concluding our phase I/II clinical studies with these encouraging results is another significant milestone we have achieved in the fight against COVID-19. We have started to invest in building a manufacturing facility so that we can maximize the number of doses available to protect people from COVID-19. Like with our other vaccines, we are committed to developing CoronaVac for global use as part of our mission of supplying vaccines to eliminate human diseases.”
Specifically, the positive results are measured by the production of neutralizing antibodies 14 days after vaccination with a seroconversion rate above 90%